Clinical Trial Update: Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a capecitabine-carboplatin-paclitaxel regimen for solid tumors, including adenocarcinoma of unknown primary; the study was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of Unknown Primary
• Cancer of Unknown Primary

Drugs mentioned

• Paraplatin (carboplatin) (carboplatin)
• Taxol (paclitaxel) (paclitaxel)
• Xeloda (capecitabine) (capecitabine)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Tumors, Unknown Primary Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-06-01